Medicine and Dentistry
Systematic Review
66%
Neoplasm
58%
Neurofibromatosis
33%
Combination Therapy
16%
Neurofibromatosis Type I
16%
Age
16%
Clinical Finding
8%
Drug Therapy
8%
Plexiform Neurofibroma
8%
Bevacizumab
8%
Exercise
8%
Tumor Microenvironment
8%
Development
8%
Cell Surface Receptor
8%
Mammalian Target of Rapamycin
8%
Drug
8%
Chemotherapeutic Agent
8%
Vestibular Schwannoma
8%
Selumetinib
8%
Neurofibromatosis Type II
8%
Reading
8%
Mitogen-Activated Protein Kinase
8%
Nursing and Health Professions
Neoplasm
58%
Patient
33%
Neurofibromatosis
33%
Combination Therapy
16%
Inpatient
16%
Child
16%
Neurofibromatosis Type 1
16%
Clinician
8%
Medline
8%
Practice Guideline
8%
Drug Development
8%
Embase
8%
Web of Science
8%
Drug
8%
Procedures
8%
Tumor Microenvironment
8%
Bevacizumab
8%
Acoustic Neuroma
8%
Selumetinib
8%
Pharmacology, Toxicology and Pharmaceutical Science
Clinical Trial
100%
Neoplasm
58%
Neurofibromatosis
33%
Neurofibromatosis Type 1
16%
Bevacizumab
8%
Drug
8%
Cell Surface Receptor
8%
Tumor Microenvironment
8%
Acoustic Neuroma
8%
Selumetinib
8%
Neurofibromatosis Type 2
8%
Neuroscience
Neurofibromatosis
41%
Neurofibromatosis Type 1
16%
Neurofibroma
8%
Bevacizumab
8%
Acoustic Neuroma
8%
Cell Surface Receptor
8%
Selumetinib
8%
PI3K/AKT/mTOR Pathway
8%
Psychology
Clinical Trial
50%
Systematic Literature Review
33%
Children
8%
Inclusion
8%